{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.28","upperLimit":"35.55","value":"25.10"},{"groupId":"OG001","lowerLimit":"11.70","upperLimit":"24.87","value":"15.34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"This measure looks at how long participants with PD-L1 positive tumors (meaning their tumor cells have at least 1% PD-L1, as determined by a laboratory test called immunohistochemistry or IHC) live after being placed into a treatment group in the sub-study.\n\nOverall Survival (OS) is defined as the time between the date a participant is randomized (assigned to a treatment group) and the date of death from any cause. For participants without documentation of death, OS will be measured up to the last date the participant was known to be alive. If a participant was randomized but had no follow-up information, OS will be counted from the date of randomization.\n\nThis helps to understand whether the treatment can help people with PD-L1 positive tumors live longer. The results are reviewed by independent experts who do not know which treatment each participant received, using standard criteria for measuring tumor response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Nivolumab 360 mg in combination with Standard of Care treatment every 3 weeks (Q3W) for up to 6 cycles followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Sub-study","id":"OG000","title":"Treatment 3"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Sub-study","id":"OG001","title":"Treatment 4"}],"paramType":"MEDIAN","populationDescription":"All PD-L1 \\>= 1% Randomized Participants - Sub-study","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)","title":"Overall Survival (OS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] by Programmed Death-Ligand 1 (PD-L1) Expression at ≥1% Expression by Immunohistochemistry (IHC) for Sub-study","type":"SECONDARY","unitOfMeasure":"Months"}